Featured Courses

Minimally Invasive Procedures in the Outpatient Setting: Applying Shared Decision Making for a Broad Range of Patients with BPH

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), AAPA Category 1 CME Credit

1.25 CME CE: Three experts review strategies for identifying patients with BPH and clinical data on minimally invasive procedures. Exp 4/16/2024

Anemia in CKD: Looking to the Future with HIF-PHIs | myCME

AMA PRA Category 1 Credit(s)^TM, ABIM MOC Points, ANCC Contact Hour(s)

1.00 CME CE: Discusses etiology of anemia in CKD and efficacy and safety data for HIF-PHIs in late-stage development for the management of CKD-related anemia. Exp 12/19/23

Examining CKD Screening, Treatment and Real-World Practice | myCME

AMA PRA Category 1 Credit(s)^TM

1.00 CME: Regular screening of UACR and adding finerenone to SGLT2 inhibitors can greatly impact T2D at risk for CKD. Join faculty as they discuss three patient cases. Exp 12/22/23

Better Education on Glomerular Disease | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

1.00 CME CE: Carla Nester, MD, and Andrew Bomback, MD, delve into the rare and difficult-to-diagnose disease state of C3 glomerulopathy, a membranoproliferative form of glomerulonephritis. Exp 12/15/23

Advancing Care of Type 2 Diabetes and Chronic Kidney Disease | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.50 CME CE: John Anderson, MD, joins Drs. Bakris and Buse to lead the discussion of 2 cases of patients with diabetic kidney disease. Exp 2/6/24

Autosomal Dominant Polycystic Kidney Disease and Nurses’ Role | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

1.00 CME CE: Expert faculty provide clinical insight on ADPKD management, highlight best practices in diagnosis and treatment, and discuss therapeutics. Exp 6/29/24

Treatments to Improve Care for Patients with Anemia in CKD | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

1.00 CME CE: Anemia is associated with major complications for patients with CKD. In this CME program, experts discuss emerging therapies for CKD. Exp 6/28/24

Advancements in Chronic Kidney Disease Treatment | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

1.00 CME CE: Learn how to monitor patients with CKD and learn guideline- and data-driven strategies to protect patients’ renal and cardiovascular health. Exp 6/13/24

Nonsteroidal MRAs for Residual Risk in CKD | myCME

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

0.25 CME CE: Nonsteroidal MRAs are available for patients with CKD of T2D. Learn how to identify appropriate patients and incorporate therapy into overall management. Exp 6/15/24

Management of Hyperkalemia in High-Risk Patients | myCME

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

0.25 CME CE: Hyperkalemia is common among patients with CKD, HF, and hypertension. Potassium binding agents may help overcome the challenges. Exp 6/5/24

Impact and Options of Residual Risk in CKD | myCME

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

0.25 CME CE: In CKD and T2D, overactivation of the MR drives further renal disease and increases cardiovascular risk. Newer treatment options targeting MR are available. Exp 6/15/24

Hyperkalemia and the Limitations of Treatment | myCME

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

0.25 CME CE: Hyperkalemia is a chronic complication among high-risk patient populations. Substantial limitations exist in traditional treatment. Exp 6/5/24